Assignee
APOGENIX AG
DE·20 granted patents·9 pending applications·5 citations·filing 2016–2021
Top patents by PatentIndex Score
29 records- 0186US10640543B2CD27 ligand (CD27L) single-chain fusion polypeptidesAPOGENIX AG·Filed 2018·Granted May 5, 2020·1 cites·11 claims
- 0282US10683338B2Single-chain TL1A receptor agonist proteinsAPOGENIX AG·Filed 2018·Granted Jun 16, 2020·2 cites·11 claims
- 0380US10118953B2Glucocorticoid-induced tumor necrosis factor receptor ligand (GITRL) single-chain fusion polypeptidesAPOGENIX AG·Filed 2017·Granted Nov 6, 2018·1 cites·13 claims
- 0477US10000550B2GITRL-collectin fusion proteins and encoding nucleic acidsAPOGENIX AG·Filed 2016·Granted Jun 19, 2018·1 cites·22 claims
- 0576US11214605B2Light single-chain fusion polypeptides, encoding nucleic acid molecules and host cellsAPOGENIX AG·Filed 2020·Granted Jan 4, 2022·0 cites·11 claims
- 0673US10519208B2CD40L single-chain fusion polypeptides and encoding nucleic acidsAPOGENIX AG·Filed 2019·Granted Dec 31, 2019·0 cites·12 claims
- 0767US10519217B2CD27L collectin fusion proteins and encoding nucleic acidsAPOGENIX AG·Filed 2018·Granted Dec 31, 2019·0 cites·20 claims
- 0867US10370441B2Nucleic acids encoding artificial signal peptides and methods of production thereofAPOGENIX AG·Filed 2018·Granted Aug 6, 2019·0 cites·6 claims
- 0965US9725495B2CD27 single chain molecules and encoding nucleic acidsAPOGENIX AG·Filed 2016·Granted Aug 8, 2017·0 cites·16 claims
- 1065US2017081381A1Single-chain fusion polypeptide comprising trailAPOGENIX AG·Filed 2016·Application pending·0 cites
- 1164US11149075B2Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) receptor agonist proteinsAPOGENIX AG·Filed 2020·Granted Oct 19, 2021·0 cites·21 claims
- 1264US10793616B2Single-chain CD40-receptor agonist proteinsAPOGENIX AG·Filed 2017·Granted Oct 6, 2020·0 cites·24 claims
- 1363US10683332B2Single-chain light receptor agonist proteinsAPOGENIX AG·Filed 2018·Granted Jun 16, 2020·0 cites·10 claims
- 1463US9908928B2Artificial signal peptideAPOGENIX AG·Filed 2016·Granted Mar 6, 2018·0 cites·6 claims
- 1561US2021032309A1Single-chain cd40-receptor agonist proteinsAPOGENIX AG·Filed 2020·Application pending·0 cites
- 1661US2021246190A1Single-chain cd137-receptor agonist proteinsAPOGENIX AG·Filed 2020·Application pending·0 cites
- 1760US10870688B2Single-chain CD137-receptor agonist proteinsAPOGENIX AG·Filed 2018·Granted Dec 22, 2020·0 cites·15 claims
- 1860US10844108B2Single-chain CD27-receptor agonist proteinsAPOGENIX AG·Filed 2018·Granted Nov 24, 2020·0 cites·16 claims
- 1960US9657083B2Composition comprising a mixture of CD95-Fc isoformsAPOGENIX AG·Filed 2016·Granted May 23, 2017·0 cites·16 claims
- 2059US2020331979A1Single-chain light receptor agonist proteinsAPOGENIX AG·Filed 2020·Application pending·0 cites
- 2159US2021061880A1Single-chain cd27-receptor agonist proteinsAPOGENIX AG·Filed 2020·Application pending·0 cites
- 2257US2023212260A1Multi-specific immune modulatorsAPOGENIX AG·Filed 2021·Application pending·0 cites
- 2356US11014991B2Monoclonal anti-CD95L (cluster of differentiation 95 ligand) antibodyAPOGENIX AG·Filed 2019·Granted May 25, 2021·0 cites·10 claims
- 2456US10533043B2Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist proteinsAPOGENIX AG·Filed 2018·Granted Jan 14, 2020·0 cites·22 claims
- 2552US10428154B2Monoclonal anti-CD95L antibodyAPOGENIX AG·Filed 2018·Granted Oct 1, 2019·0 cites·10 claims
- 2651US10266600B2Diagnostic anti-CD95L antibodyAPOGENIX AG·Filed 2016·Granted Apr 23, 2019·0 cites·12 claims
- 2751US2017166648A1Inhibitors of the cd95 signaling pathway for treatment of mdsAPOGENIX AG·Filed 2016·Application pending·0 cites
- 2844US2018230196A1Single-chain ox40-receptor agonist proteinsAPOGENIX AG·Filed 2018·Application pending·0 cites
- 2933US2017106048A1Combination of CD95/CD95L inhibition and Cancer ImmunotherapyAPOGENIX AG·Filed 2016·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →